abs375.txt	most	ovarian	cancer	patients	respond	well	to	initial	platinum-based	chemotherapy	however		within	a	year		many	patients	experience	disease	recurrence	with	aplatinum	resistant	phenotype	that	responds	poorly	to	second	line	chemotherapies	as	a	result		new	strategies	to	address	platinum	resistant	ovarian	cancer	(proc)are	needed		herein		we	report	that	np	co-delivery	of	cisplatin	(cp)	andwortmannin	(wtmn)		a	dna	repair	inhibitor		synergistically	enhanceschemoradiotherapy	(crt)	and	reverses	cp	resistance	in	proc		we	encapsulated	thisregimen	in	fda	approved	poly(lactic-co-glycolic	acid)-poly(ethylene	glycol)(plga-peg)	nps	to	reduce	systemic	side	effects		enhance	cellular	cp	uptake	improve	wtmn	stability		and	increase	therapeutic	efficacy		treatment	ofplatinum-sensitive	ovarian	cancer	(psoc)	and	proc	murine	models	with	thesedual-drug	loaded	nps	(dnps)	significantly	reduced	tumor	burden	versus	treatmentwith	combinations	of	free	drugs	or	single-drug	loaded	nps	(snps)		these	resultssupport	further	investigation	of	this	np-based		synergistic	drug	regimen	as	ameans	to	combat	proc	in	the	clinic	
